For example, by specifically identifying and targeting ARHGAP45-expressing tumor cells, TCR-T cells can directly attack these highly migratory and invasive cancer cells, thereby reducing the risk of metastasis and improving overall therapeutic outcomes. This evidence concerns the gene ARHGAP45 and neoplasm.